 The rate of progression of renal insufficiency for the Active Treatment Group assessed via serial measurements of eGFR pre-randomization through 12 months after the last NKA injection will be compared against that of the Deferred Treatment Group ie, contemporaneous control group. In addition, each subjects baseline rate of eGFR decline derived from adequate historical, clinical data will be compared against the individual subjects rate of eGFR decline through 12 months following the final NKA treatment. The rate of progression of renal insufficiency from subjects if any who received a single NKA injection may be compared against that from subjects who received two NKA injections. 